Loading
A phase 2 trial of Fulzerasib and Ivonescimab in KRAS G12C-mutant non-small-cell lung cancer, run by Shanghai Chest Hospital, not yet recruiting.
A Multicenter, Single-arm Phase II Study to Evaluate the Efficacy and Safety of Fulzerasib (IBI351) in Combination With Ivonescimab (AK-112) in First-line Treatment of Advanced or Metastatic Non-small Cell Lung Cancer Patients With KRAS G12C Mutation is a phase 2 interventional study registered as NCT06936644 by Shanghai Chest Hospital, with 39 participants planned, started 2025-04-30 and due to reach its primary completion in 2027-04-30. Interventions recorded: IBI351+AK112. Conditions recorded: KRAS G12C Lung Cancer.
Linked to the drug Fulzerasib because the registry names it among its interventions and KRAS G12C-mutant non-small-cell lung cancer among its conditions. Registry record only: no result has been read by an editor.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Fulzerasib, KRAS G12C-mutant non-small-cell lung cancer and the tag pipeline.
Shares Fulzerasib and the tag pipeline.
Shares Ivonescimab and the tag pipeline.
Shares Ivonescimab and the tag pipeline.
Shares KRAS G12C-mutant non-small-cell lung cancer and the tag pipeline.
Shares KRAS G12C-mutant non-small-cell lung cancer and the tag pipeline.
Shares KRAS G12C-mutant non-small-cell lung cancer and the tag pipeline.
Shares KRAS G12C-mutant non-small-cell lung cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/